Details of the Drug Formulations

General Information of Drug (ID: DMXLBCQ)

• Drug Name: Sodium phenylbutyrate Drug Info
• Synonyms: Ammonaps; Buphenyl; EL-532; Sodium 4-phenylbutyrate; Sodium phenylbutyrate, Elan; Sodium phenylbutyrate, Medicis; Sodium phenylbutyrate, Ucyclyd; VP-101; Sodium 4-phenylbutyrate, Elan; Sodium 4-phenylbutyrate, Ucyclyd; Sodium phenylbutyrate (cancer), MacroChem/Access; Sodium phenylbutyrate (cancer), Virium/ Somanta; Sodium phenylbutyrate (cancer), Virium/Access Pharmaceuticals; Sodium 4-phenyibutyrate (cancer), MacroChem/Access; Sodium 4-phenylbutyrate (cancer), Virium/ Somanta; Sodium 4-phenylbutyrate (cancer), Virium/Access Pharmaceuticals

Indication

Disease Entry	ICD 11	Status	REF
Spinal muscular atrophy	8B61	Approved	[1]
Spinal muscular atrophy, type II		Approved	[2]
Urea cycle disorder	5C50.A	Approved	[2]
Citrullinemia		Investigative	[2]

• Cross-matching ID:
  PubChem CID: 5258
  ChEBI ID: CHEBI:75316
  CAS Number: 1716-12-7
  TTD ID: D0P2GK
  ACDINA ID: D00633

Full List of Drug Formulations Containing This Drug

Sodium phenylbutyrate 500 mg tablet

Company	Formulation ID	FDA Description
Par Pharmaceutical	F20311	Calcium stearate; Magnesium stearate; Silicon dioxide; Cellulose, microcrystalline
Hyperion Therapeutics	F20312	Magnesium stearate; Silicon dioxide; Cellulose, microcrystalline
Mikart	F20313	Magnesium stearate; Silicon dioxide; Cellulose, microcrystalline

References

• [1] ClinicalTrials.gov (NCT00533559) Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl. U.S. National Institutes of Health.
• [2] Sodium phenylbutyrate FDA Label